Life Expectancy for Stage IV Pancreatic Adenocarcinoma

Baseline Prognosis Without Treatment

• Patients with stage IV pancreatic adenocarcinoma have a median survival of approximately 6-8 months, with 1-year survival of 15% and 5-year survival of only 2% 1, 2
• Median overall survival for stage IV disease is approximately 5.8-7 months from diagnosis 1, 2
• One-year survival rate is 15% 1, 2
• Five-year survival rate is 2% 1, 2

Impact of Treatment on Survival

• The American College of Radiology notes that the prognosis improves substantially with systemic chemotherapy, though outcomes remain poor overall, with FOLFIRINOX or gemcitabine plus nab-paclitaxel extending median survival to approximately 8-12 months for patients with good performance status 3
• Gemcitabine monotherapy extends median survival to approximately 6.6 months for patients with moderate performance status 3

Key Prognostic Factors That Modify Survival

• Performance status is the single most important prognostic factor and should guide treatment decisions, with ECOG 0-1 patients eligible for aggressive combination chemotherapy with significantly better outcomes 3, 4
• The American College of Radiology recommends that patients with ECOG 2 or higher performance status be limited to single-agent therapy or supportive care only, with median survival of 3-4 months 3

Clinical Context and Caveats

• The American College of Radiology states that 80-85% of patients who present with advanced disease are not candidates for surgical resection 1, 5
• Pancreatic adenocarcinoma remains the fourth leading cause of cancer-related death in the United States, with a prognosis that remains extremely poor despite treatment advances 1, 2